NCT06045975 - Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by by Percutaneous Ablation Procedure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

September 28, 2027

Study Completion Date

September 28, 2028

Conditions

HCC - Hepatocellular Carcinoma

Interventions

DRUG

Durvalumab/Tremelimumab in neoadjuvant and Durvalumab in adjuvant setting

"* Durvalumab 1500 mg/Tremelimumab 300 mg infusion in a neoadjuvant setting followed by PA procedure at Day 30+/-7 days~* 11 monthly Durvalumab 1500 mg infusions."

Trial Locations (1)

93000

RECRUITING

Hospitl Avicenne, Bobigny